Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.

  • Akebia Therapeutics' Consolidated Net Income rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Consolidated Net Income stood at $540000.0, which was up 10269.47% from $247000.0 recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Consolidated Net Income high stood at $29.0 million for Q2 2022, and its period low was -$84.3 million during Q2 2021.
  • In the last 5 years, Akebia Therapeutics' Consolidated Net Income had a median value of -$18.0 million in 2024 and averaged -$26.1 million.
  • Per our database at Business Quant, Akebia Therapeutics' Consolidated Net Income skyrocketed by 13444.48% in 2022 and then plummeted by 381400.65% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Consolidated Net Income (Quarter) stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then surged by 109.44% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then skyrocketed by 102.37% to $540000.0 in 2025.
  • Its last three reported values are $540000.0 in Q3 2025, $247000.0 for Q2 2025, and $6.1 million during Q1 2025.